

**V.N.KARAZIN KHARKIV NATIONAL UNIVERSITY**  
**SCHOOL OF MEDICINE**  
**DEPARTMENT OF INTERNAL MEDICINE**



**DRUG MANAGEMENT OF PATIENT WITH  
HEART FAILURE AFTER  
CARDIAC PACING**

Speaker: Student of 5<sup>th</sup> course Yazan Dwayat

Scientific advisers: ass. prof. Zhuravka N.V.


ass. prof. Kanishcheva O.V.

prof. Yabluchanskyi M.I.

# Introduction 1

- Heart Failure (HF) is a clinical syndrome characterized by typical symptoms (e.g. breathlessness, ankle swelling and fatigue) that may be accompanied by signs (e.g. elevated jugular venous pressure, pulmonary crackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress.


# Introduction 2

- Treatment of HF includes interventions in lifestyle, drug therapy, cardiac resynchronization therapy (CRT), as well as cardiac surgery, with priority being given to the first two.
  - Pacemakers are well-established therapies of severe bradyarrhythmias, and one of them is complete AV block.
  - In patients with AV block and HF placing an electrode in the intraventricular septum can lead to CRT effect achievement.
- 

# Goal

- ▶ To overview management of the patient with heart failure and cardiac pacemaker, implanted due to AV block of III degree on the example of clinical case.

# Our Patient

- ▶ Name: B.S.N.
  - ▶ Gender: female.
  - ▶ Age: 78 years old.
  - ▶ Occupation: retired.
  - ▶ Admitted to the hospital #5 on 26th of September 2017.
- 

# Complaints

- ▶ Oedema of the shins.
- ▶ Cough and dyspnea at minimal exertion, absent at rest.


# Anamnesis Morbi 1

- ▶ Arterial hypertension more than 10 years (max 200/100 mm Hg, adapted to 130-140/80 mm Hg) Patient took enalapril + hydrochlorothiazide 10mg/12.5 mg once a day.
- ▶ 2011 - myocardial infarction. The AV block of III<sup>d</sup> degree with Adams-Stokes Syndrome was diagnosed but patient refused the cardiac pacemaker implantation.
- ▶ According to the patient, she took “a bunch of pills” every day, which she cannot remember the name of (the record is not available).

# Anamnesis Morbi 2

- ▶ 2014 - second myocardial infarction (the record is not available).
- ▶ Summer 2017 – worsening of the disease, with complaints of dry cough and shortness of breath, worsened by exertion, legs oedema, frequent fainting.

# ECG (23.08.17)



**Conclusion:**  
AV block of 3<sup>d</sup>  
degree with VR 27  
bpm, AR 85 bpm.  
QRS 114 msec  
QT 572 msec  
No signs of focal  
myocardial lesion.

# Anamnesis Morbi 3

- ▶ 23.08.17 the cardiac pacemaker was implanted, in the DDDR pacing mode, pacing threshold: 1<sup>st</sup> electrode – 0.5 V, 2<sup>nd</sup> – 0.6 V. The first electrode was set in the interventricular septum, the second – in the anterolateral wall of the right atrium.
- ▶ DDDR is a dual-chamber pacemaker means the pacemaker is pacing electric activity in the atrium and the ventricle and it is sensing activity in each of them.
- ▶ After implantation of cardiac pacemaker the symptoms were not completely controlled, and patient was hospitalized to the cardiology department to correct the treatment.

# Anamnesis Vitae

- ▶ Denies malaria, tuberculosis, diabetes mellitus, dermatovenerologic diseases.
- ▶ 1956 - Hepatitis A.
- ▶ Patient has no allergies and no reactions to drugs and medication.
- ▶ Denies smoking, alcohol intake and drug addiction.
- ▶ Family history is significant for cardiovascular diseases.
- ▶ Meningioma of the left parietal region.

# Physical examination 1

- Temperature 36,7°C
- PS 78 bpm (both hands)
- BP 130/80 mm Hg (both hands)
- Respiratory rate 18 pm
- Height 166 cm
- Weight 82 kg
- BMI 29 kg/m<sup>2</sup>

# Physical examination 2

- General condition:  
Her mood, orientation in space, posture and development are normal.
- Skin and mucous membranes:  
Skin, subcutaneous fat tissue, nails, mucous membranes, tongue are normal.
- Musculoskeletal system examination unremarkable.
- Peripheral lymph nodes are not palpable.
- The thyroid is not palpable.
- **Oedema of lower third of both shins.**

# Physical examination 3

## ➤ Respiratory System:

- pulmonary percussion –normal
- auscultation - weakened vesicular breathing, no adventitious sounds

## ➤ Cardiovascular system:

- heart borders extended to the left on 1,5 cm of mid clavicular line, HR =78 bpm, regular.
- no pulse deficiency, heart sounds are muted, accent of the II tone above the aorta.

# Physical examination 4

- Gastrointestinal system:
  - abdomen is soft, painless, symmetrical, no discrepancies of the abdominal muscles, no visible peristalsis;
  - liver edge is smooth, painless, palpated at the costal arch, spleen and pancreas are not palpable;
  - stool is normal.
- Urinary system:
  - kidneys are not palpable. Pasternatsky's sign negative on both sides. Urination is normal.

# Plan of survey

- CBC
- Urinalysis
- FPG (fasting plasma glucose)
- Liver function tests (LFT)
- Renal function tests (RFT)
- Lipid profile
- EchoCG
- ECG (12-lead)
- Chest X-ray
- Serum electrolyte levels
- B-type natriuretic peptide (BNP)
- N-terminal pro-B-type (NT-proBNP)
- Doppler flow ultrasonographic study

European Heart Journal (2016) 37, 2129–2200 doi:10.1093/eurheartj/ehw128

Prescribed

Recommended

# CBC (27.09.17)

Parameters	Result	Normal range
Hemoglobin	151	F 120 - 140 g/ l
Erythrocytes	5,29	F 3,9-4,7 T/ l
Hematocrit	45,0	35 – 47 5%
Leukocytes	6,2	4,0 – 9,0 g/L
ESR	4	F 2-15 mm/h
Stab neutrophils	1,1	1-6 %
Segmented neutrophils	47	47-72 %
Eosinophils	2,5	0,5-5,0%
Basophils	1,9	1-1,0 %
Lymphocytes	36	19-37%
Monocytes	8,9	3-11 %
Platels	261	180-320 g/L

Conclusion: increase of hemoglobin level, erythrocytosis.

# Urinalysis (27.09.17)

Parameters	Result	Normal range
Specific gravity	1,030	1,001-1,040
Reaction	6,0	5,0-7,0
Protein	Not detected	0,033 g/ l
Glucose	Absent	Absent
Erythrocytes	0	0-2
Leucocytes	1-2	6-8

Conclusion: all parameters within the normal range.

# Biochemical blood test (27.09.17)

Parameters	Result	Normal range
Total bilirubin	18,6	2-20 $\mu\text{mol/l}$
AlAt	20,1	8-40 U/L
AsAt	27,5	8-38 U/L
Creatinine	81	60-123 $\mu\text{mol/l}$
Glucose	5,8	4,2-6,1 $\mu\text{mol/l}$

Conclusion: all parameters within the normal range.

# Lipid profile (27.09.17)

Parameters	Result	Normal range
Cholesterol	5,41	< 5.2 mmol/l
VLDL	0.65	< 1.0 mmol/l
LDL	2.98	< 3.5 mmol/l
HDL	1.77	> 0.9 mmol/l
Triglycerides	1.45	≤ 2.3 mmol/l

Conclusion: hypercholesterolemia, type I.

# ECHOCARDIOGRAPHY(27.09.17)

INDEX	RESULT	NORMAL
Aorta	31	20-37mm
Aortic valve	18	17-26mm
Mitral valve	31	26-35mm
Left atrium	33.0	To 38 mm
End Diastolic velocity	100	50-180 cm/s
End Systolic volume	50.0	35-55mm
Left Ventricle Wall	13.2	6-11 mm
Ejection Fraction	48	55-78%
Left Ventricle amplitude	8,8	7-13mm
Intraventricular septum	12	6-11 mm
Right atrial diameter	41	≤45mm
Right Ventricle diameter	24	9-26mm

Conclusion: atherosclerotic cardiosclerosis, aorta atherosclerosis, LV hypertrophy. Dyssynergic areas were not identified.

# ECG (27.09.17)



## Conclusion:


Pacemaker rhythm,  
bipolar stimulation  
of the ventricles

HR 89 bpm

QRS 144 msec

QT 364 msec

# Chest X-Ray(27.09.17)



**Conclusion:** no pathological changes in the lungs. Pacemaker in left subcostal area, visible electrode in the right heart chambers.

# Basic clinical syndromes

- Atherosclerosis (sclerotic changes of aorta and aortic valve).
- Arterial hypertension.
- Condition after the implantation of cardiac pacemaker (23.08.17) due to AV-block III degree with Adams-Stokes syndrome.
- Heart failure.
- Hypercholesterolemia, type I.
- Overweight.

# Clinical diagnosis

## according to current classifications

- Ischemic heart disease. Atherosclerotic and post infarction (2011, 2014) cardiosclerosis. Aorta atherosclerosis.
- Heart failure with reduced ejection fraction (48%), III FC, stage C.
- Arterial hypertension, III stage, hypertensive heart (LVH), 3 degree.
- CVD risk very high.
- Permanent pacemaker (23.08.17) due to AV-block III degree with Adams-Stokes syndrome.
- Hypercholesterolemia, type I.
- Overweight.

# Hospital treatment

- ▶ Clopidogrel 75 mg once a day
- ▶ Bisoprolol 2,5 mg in the morning
- ▶ Torasemide 2,5 mg in the morning
- ▶ Valsartan 40mg twice a day
- ▶ Rosuvastatin 5 mg in the evening
- ▶ Meldonium 5,0 ml IV № 10
- ▶ Pentoxifylline 5,0 ml + 100,0 ml saline IV infusion № 2

# Our recommendations 1

## LIFESTYLE MODIFICATION

- DASH diet
  - a diet rich in fruits, vegetables, low fat or nonfat dairy
  - includes mostly whole grains, lean meats, fish and poultry, nuts and beans
- Daily aerobic activity
  - 25 to 30 minutes walking at a fast pace

# Our recommendations 2

## PHARMACOLOGICAL TREATMENT


- Torasemide 2,5 mg in the morning (ones in 3 days)
- Bisoprolol 2,5 mg in the morning
- Rosuvastatin 5 mg in the evening
- Valsartan 40mg twice a day
- **Acetylsalicylic acid** 75 mg once a day in the evening

# Follow-up


(two months later)

- ▶ Patient takes medication regularly
- ▶ Patient's condition is much better: no oedema, no cough, exercise tolerance increased.

# Important remark





ECG before pacing



ECG after pacing

## PACEMAKER INSERTION



# Conclusion

- ▶ Precept “*festina lente*” is important in all medical practice, and in interventional cardiology - in the first place.
- ▶ Cardiac pacemaker in the presence of possible solutions to the problem of arrhythmias and HF it does not cancel, but modifies the medical support of patients.
- ▶ To prolong patient's life, it's very important to establish a timely diagnosis and prescribe appropriate therapy.

**THANK YOU FOR ATTENTION!**

